banner
Department of Surgery »  Faculty »  Division Chiefs »  Hobart W. Harris, M.D., M.P.H.

Hobart W. Harris, M.D., M.P.H.

Professor and Chief, Division of General Surgery
Vice-Chair, Department of Surgery
J. Engelbert Dunphy Endowed Chair in Surgery

Contact Information

513 Parnassus Avenue
San Francisco, California 94143-0104
Clinical Telephone: (415) 353-2161
New Patient Coordinator Telephone: (415) 353-2804
Academic Telephone: (415) 514-3891
Fax: (415) 476-0164
e-mail: hobart.harris@ucsfmedctr.org

Education

  • 1975-1979 Harvard College, Cambridge, MA       A.B. Biology
  • 1979-1983 Harvard Medical School, Boston, MA     M.D. Medicine
  • 1983-1984 Harvard School of Public Health, Boston, MA M.P.H. General Studies

Residencies

  • 1984-1985 University of California, San Francisco Intern Surgery
  • 1985-1993 University of California, San Francisco Resident Surgery

Fellowships

  • 07/1993-12/1993 University of Hong Kong, Queen Mary Hospital, Hong Kong, P.R.C. Hepatobiliary Surgery
  • 02/2005-07/2005 University of Louisville, Louisville, KY ERCP

Board Certifications

  • American Board of Surgery, 1994

Clinical Expertise

Biography

Dr. Hobart W. Harris is Chief of the Division of General Surgery, Vice-Chair of the Department of Surgery, and a Professor of Surgery at the University of California, San Francisco. Dr. Harris is also a Principal Investigator in the UCSF Surgical Research Laboratory at San Francisco General Hospital.

Dr. Harris is an expert in treating surgical infections and diseases of the pancreas and biliary system. His areas of expertise include pancreas and bile duct cancer, acute and chronic pancreatitis, gallstone disease, intra-abdominal sepsis and serious infections of the skin and soft tissue.

Dr. Harris earned his undergraduate, medical and public health degrees at Harvard University, then completed an internship and residency in surgery at UCSF. After residency training, he completed a fellowship in heptobiliary surgery at the University of Hong Kong, Queen Mary Hospital and joined UCSF in 1994.

His research focuses on surgical infections, innate immunity and inflammatory diseases of the pancreas. His laboratory work is supported by an NIH grant to study the role of triglyceride-rich lipoproteins in the innate host response to endotoxins, such as those released by the Gram-negative bacteria that cause the most deadly form of sepsis.

Dr. Harris is a fellow of the American College of Surgeons and is a member of numerous surgical and scientific societies including the American Surgical Association and the International Hepato-Pancreato-Biliary Association.

Research Summary

Gram negative sepsis is initiated by host exposure to endotoxin (LPS), which triggers both pro-inflammatory and regulatory responses. Whereas neutrophils and macrophages are stimulated to release cytokines (TNF, IL-1), nitric oxide and other promoters of inflammation, sepsis also induces the acute phase response, wherein hepatocytes secrete substances designed to limit the extent and severity of the inflammatory reaction. Therefore, the balance between these opposing responses defines the difference between a healthy, protective reaction versus a pathologic, potentially fatal one. Despite increasing insight into the pathophysiology of gram negative infection, sepsis remains a significant problem in Medicine, annually effecting 750,000 patients and causing over 175,000 deaths. Unfortunately, recent clinical trials employed a strategy of inhibiting a single inflammatory mediator with anti-endotoxin or anti-cytokine agents, and have been largely unsuccessful.

Efforts in the laboratory have focused on understanding the molecular basis of the "lipemia of sepsis," a facet of the acute phase response resulting from the increased production of triglyceride (TG)-rich lipoproteins by the liver. Dr. Harris hypothesizes that chylomicrons (CM) and VLDL are components of an innate host immune response to infection. Specifically, CM and VLDL bind LPS forming lipoprotein-LPS complexes that are capable of regulating the hepatocellular response to inflammatory stimuli.

Current studies examine how the CM-LPS complexes are internalized and the impact of this cytoplasmic LPS on hepatocellular function. Specifically, the research group is a) using their recently developed cell culture system to delineate the mechanisms by which CM-bound LPS is internalized by and inhibits the response of hepatocytes to cytokines, b) determining the effect of CM-bound LPS on the response of hepatocytes to acute cellular stressors, and c) examining whether CM-bound LPS inhibits cytokine-induced activation of hepatocytes by interrupting intracellular signal transduction. Whereas the acute inflammatory response is critical for the host to combat bacterial infections, this defensive response must be tightly regulated or it can culminate in shock, multiple organ failure and death. Understanding how CM protect against LPS and contribute to host homeostasis is central to the understanding of the host response to infection, and the future development of a novel therapeutic strategy based on manipulating the response of target cells to pro-inflammatory stimuli rather than blocking individual inflammatory mediators.

In addition, Dr. Harris'  research group is actively investigating the role of apolipoprotein E (apoE) as an immunomodulatory agent. Specifically, they are examining how apoE modulates the response to infection through the CD1-mediated activation of Natural Killer T lymphocytes in a rodent model of polymicrobial sepsis. These studies may provide additional evidence in support of our global hypothesis that triglyceride-rich lipoproteins are integral components of the host immune response to infection.

 

Publications

Most recent publications from a total of 73
  1. Harris HW. Clinical outcomes of biologic mesh: where do we stand? Surg Clin North Am. 2013 Oct; 93(5):1217-25. View in PubMed
  2. Harris HW. Biologic mesh for ventral hernia repair: a cautionary tale. Ann Surg. 2013 Jun; 257(6):997-8. View in PubMed
  3. Beard JH, Oresanya LB, Ohene-Yeboah M, Dicker RA, Harris HW. Characterizing the global burden of surgical disease: a method to estimate inguinal hernia epidemiology in Ghana. World J Surg. 2013 Mar; 37(3):498-503. View in PubMed
  4. Primus FE, Harris HW. A critical review of biologic mesh use in ventral hernia repairs under contaminated conditions. Hernia. 2013 Feb; 17(1):21-30. View in PubMed
  5. Harris H. Systematic review of total pancreatectomy and islet autotransplantation for chronic pancreatitis (Br J Surg 2012; 99: 761-766). Br J Surg. 2012 Jun; 99(6):767. View in PubMed
  6. Chuang KI, Corley D, Postlethwaite DA, Merchant M, Harris HW. Does increased experience with laparoscopic cholecystectomy yield more complex bile duct injuries? Am J Surg. 2012 Apr; 203(4):480-7. View in PubMed
  7. Chuang KI, Leung B, Hsu N, Harris HW. Heparin protects against septic mortality via apoE-antagonism. Am J Surg. 2011 Sep; 202(3):325-35. View in PubMed
  8. Leung B, Harris HW. NKT cells: the culprits of sepsis? J Surg Res. 2011 May 1; 167(1):87-95. View in PubMed
  9. Leung B, Harris HW. NKT cells in sepsis. Clin Dev Immunol. 2010; 2010. View in PubMed
  10. Spitzer AL, Chuang KI, Victorino GP, Kasravi B, Curran B, Lee D, Harris HW. Chylomicrons combined with endotoxin moderate microvascular permeability. Innate Immun. 2011 Feb; 17(3):283-92. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Hobart W. Harris, M.D., M.P.H.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X